gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LMATHealthcareSurgical Instruments

LeMaitre Vascular, Inc. (LMAT)

$87.92+9.08%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$87.92▲ 0.76% in range
Nov 4, 2025Low $78.80 · High $117.39Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

LeMaitre Vascular closed at $87.92 on Nov 4, up 9.08%, 25.1% below its 52-week closing high. Volume of 520.4K shares was 1.92× its 20-day average (above normal).

Split-adjusted performance: +11.2% over one month, -20.2% over six months, +1.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $70.38M, up 9.6% from a year earlier, with a net margin of 24.2%.

Short interest was 1.8M shares at the Oct 15 settlement, up 2.1% from the prior report (8.4% of float, 6.6 days to cover).

Market cap$2.01B22.9M shares
Revenue · quarter$70.4M+9.6% YoY
Diluted EPS$0.74+23.3% YoY
P/E · TTM30.6×P/S 7.7×
Net margin24.2%Gross 72.1%
Dividend yield1.14%$0.25 last paid
52-week range78.80 – 117.39−25.1% from high
Volume520.4K1.92× 20-day avg
Volatility · 60d29.9%Annualised
Short % of float8.4%6.6 days to cover
Net cash$207.1MCash $376.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +6.1%1M +11.2%3M +8.8%6M −20.2%YTD +8.4%1Y +1.2%3Y +83.5%5Y +60.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum37
Revenue growth52
Net margin94
Value (low P/E)47
Size78

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short1.8M+2.1% vs prior
Days to cover6.6Settled Oct 15
% of float8.4%
Short vol. 10d47.4%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LMATLeMaitre Vascular$87.92+9.08%−20.2%+9.6%24.2%30.6$2.01B
INSPInspire Medical Systems$66.61+7.61%+45.8%−7.9%−11.8%19.1$1.93BCompare
KMTSKestra Medical Technologies$30.50+5.14%+47.3%+59.9%−142.3%—$1.82BCompare
NVCRNovoCure Limited$14.61+8.79%−11.4%+15.7%−5.4%—$1.71BCompare
UFPTUFP Technologies$329.82+17.66%+51.2%+15.1%12.0%35.3$2.55BCompare
TNDMTandem Diabetes Care$19.05+7.93%+5.7%+5.8%−8.3%—$1.33BCompare
AORTArtivion$26.45+11.56%−23.8%+11.3%−10.7%—$1.29BCompare
ATECAlphatec Holdings$8.28+10.84%+18.5%+12.6%−2.5%—$1.27BCompare
PRCTPROCEPT BioRobotics$21.66+7.39%−12.7%+19.3%−28.4%—$1.24BCompare

News about LeMaitre Vascular

All news →
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026GlobeNewswire Inc. · Oct 12, 2026NeutralPAHC or LMAT: Which Is the Better Value Stock Right Now?Zacks Investment Research · Sep 2, 2026▼ NegativeLeMaitre Q1 2026 Financial ResultsBenzinga · May 5, 2026▲ PositiveLeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should KnowThe Motley Fool · Mar 28, 2026▲ PositiveLeMaitre to Participate at Upcoming Investor Conferences in MarchGlobeNewswire Inc. · Feb 27, 2026▲ Positive

Quick answers

What does LeMaitre Vascular do?
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons.
What is LMAT's market cap?
$2.01B, based on the Nov 4 close of $87.92.
What is LMAT's P/E ratio?
30.6× trailing-twelve-month earnings of $65.67M.
Does LeMaitre Vascular pay a dividend?
Yes. The latest regular dividend was $0.25 per share (ex-date Aug 20), an annualised yield of 1.14%.
How much of LMAT is sold short?
1.8M shares, 8.4% of float, as of Oct 15, 2026.
What sector is LMAT in?
Healthcare, in the Surgical Instruments industry.

About LeMaitre Vascular

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

HQ: Burlington, MA655 employeesListed Oct 19, 2006lemaitre.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology